Trade Names:TussiCaps Half Strength- Capsules, ER hydrocodone bitartrate 5 mg and chlorpheniramine maleate 4 mg
Trade Names:TussiCaps Full Strength- Capsules, ER hydrocodone bitartrate 10 mg and chlorpheniramine maleate 8 mg
Trade Names:Tussionex Pinnkinetic- Suspension, ER hydrocodone bitartrate 10 mg and chlorpheniramine maleate 8 mg per 5 mL
Suppresses cough reflex; stimulates opiate receptors in the CNS and peripherally blocks pain impulse generation.Chlorpheniramine
Competitively antagonizes histamine at H 1 receptor sites.
Relief of cough and upper respiratory tract symptoms associated with allergy or a cold.
Hypersensitivity to any component of the product; children younger than 6 yr of age ( Tussionex ).
One 10/8 mg capsule every 12 h; max, two 10/8 mg capsules per 24 h.Tussionex
5 mL every 12 h; max, 10 mL per 24 h.Children 6 to 11 yr of age
One 5/4 mg capsule every 12 h; max, two 5/4 mg capsules per 24 h.Tussionex
2.5 mL every 12 h; max, 5 mL per 24 h.
Store at 59° to 86°F. Keep tightly capped.
Increased CNS depression (eg, drowsiness) may occur.Anticholinergics
Risk of paralytic ileus may be increased.MAOIs, tricyclic antidepressants
The effects of these agents or hydrocodone may be increased.
May interfere with diagnostic test results for skin tests using allergen extracts.
Anxiety, dizziness, drowsiness, dysphoria, euphoria, fear, impaired mental and physical performance, lethargy, mental clouding, mood change, psychic dependence, sedation.
Constipation, nausea, vomiting.
Spasm of vesical sphincter, ureteral spasm, urinary retention.
Chest tightness, dryness of the pharynx.
Category C .
Safety and efficacy not established in children younger than 6 yr of age.
Use with caution, usually starting at the low end of the dosage range, because of the greater frequency of decreased hepatic, renal, or cardiac function, and concomitant diseases or other drug therapy.
Use with caution in postoperative, elderly, or debilitated patients, and in patients with narrow-angle glaucoma, asthma, prostatic hypertrophy, severe hepatic or renal function impairment, hypothyroidism, Addison disease, pulmonary disease, or urethral stricture.
Diagnosis or clinical course of patients with acute abdominal conditions may be obscured.
Has abuse potential and may be habit-forming.
Opioids may elevate cerebrospinal fluid pressure, which may be markedly exaggerated in the presence of head injury, other intracranial lesions, or preexisting increase in intracranial pressure.
Opioids may result in obstructive bowel disease, especially in patients with underlying intestinal motility disorder.
Dose-related respiratory depression can occur.
Apnea, bradycardia, cardiac arrest, circulatory collapse, cold and clammy skin, death, extreme somnolence progressing to stupor or coma, hypotension, respiratory depression, skeletal muscle flaccidity.
Copyright © 2009 Wolters Kluwer Health.